Open AccessDasatinib Responses Durable in Chronic-Phase CML Patients Resistant or Intolerant to Imatinib
Author(s) -
Mark Fuerst
Publication year - 2008
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000312319.31714.43
Subject(s) - dasatinib , nilotinib , imatinib , medicine , chronic myelogenous leukemia , tyrosine kinase inhibitor , oncology , clinical trial , imatinib mesylate , tyrosine kinase , pharmacology , cancer , leukemia , myeloid leukemia , receptor